After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or ...
Mereo BioPharma (MREO) announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. Neither study ...
Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.
Claimed as the first space qualified 3-GHz phase locked loop ICs, the PE9701 and PE9702 are integer-N PLLs featuring 10/11 dual modulus pre-scalers, phase comparators and counter values targeted at ...
Abstract: In this paper, the design, concept and experimental validation of the performances of a piezoelectric resonant microelectromechanical systems (MEMS) phase comparator is presented. Compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback